GlassScriptPhysician profile
Daniel J Legault
NPI 1649204892
$2,576.48
in general payments reported to CMS, 2019-2025
27 companies · $18.99 in 2025
The $18.99 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $273 · 2021: $424 · 2022: $603 · 2023: $680 · 2024: $76.53 · 2025: $18.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736 · Education: $39.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.01 |
| Education | $39.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $427.08 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $322.14 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $171.02 | 2019-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $166.55 | 2022-2023 | Tarpeyo |
| Glaxosmithkline, LLC. | $124.88 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $120.12 | 2020-2023 | Acthar |
| Aurinia Pharma U.S., INC. | $115.98 | 2021-2023 | Lupkynis |
| Akebia Therapeutics INC | $105.31 | 2019-2022 | |
| Vifor Pharma, INC. | $102.44 | 2019-2023 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $100.75 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.94 | 2022-2024 | |
| Mallinckrodt Enterprises LLC | $85.21 | 2019 | |
| Travere Therapeutics, INC. | $84.62 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.16 | 2022-2023 | Jardiance |
| Fresenius USA Marketing, INC. | $66.35 | 2020-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $60.92 | 2019-2021 | |
| Daiichi Sankyo INC. | $53.93 | 2020-2022 | |
| Novo Nordisk INC | $53.00 | 2023 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $50.93 | 2022-2023 | Rayaldee |
| Janssen Pharmaceuticals, INC | $31.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $31.03 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.28 | 2019 | |
| Genzyme Corporation | $23.50 | 2023 | |
| Shire North American Group INC | $21.90 | 2019 | |
| Genentech USA, INC. | $19.75 | 2021 | |
| Ardelyx, INC. | $14.19 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Legault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.